Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Phosphodiesterases (PDEs) was found to be involved in a variety of cancer pathologies by modulating the degradation of levels of cAMP/cGMP. However, the prognostic significance and biological effect of
PDE4a
in hepatocellular carcinoma (HCC) have not been understood completely. In the present study,
PDE4a
expression was detected in a cohort of HCC and matched adjacent liver tissues (n = 210) by immunohistochemistry staining and Western immunoblotting assay, And
in vitro
experiments were conducted to determine the effect of
PDE4a
on metastatic capacity of HCC cells. The data here displayed that the majority of HCC patients had higher
PDE4a
expression in tumor tissues compared to matched adjacent liver tissues and enhanced
PDE4a
expression in tumor tissues was associated positively with HBV infection, liver cirrhosis, higher serum AFP level, advanced TNM stage, vascular embolus, intrahepatic metastases and portal vein tumor thrombus (PVTT). Survival analyses suggested that higher
PDE4a
was indicated the poor prognosis of HCCs after liver resection. Ectopic expression of
PDE4a
in Huh7 cells leaded to significant repression of E-cadherin and up-regulated the expression of N-cadherin and Vimentin, and facilitated migration and invasion abilities. Silencing
PDE4a
in MHCC97h cells acquired the opposite results. Taken together,
PDE4a
triggered
EMT
in HCC cells and acted as a predictive factor candidate and a potential therapeutic target for HCC.
...
PMID:PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. 3002 35